IMJUDO (tremelimumab-actl) injection
Imjudo is a cancer medicine. It is used to treat: hepatocellular carcinoma (a type of liver cancer) in adult patients who have not been treated before and whose disease is advanced or unresectable (cannot be removed by surgery). IMJUDO (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 2022
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
IMJUDO (tremelimumab-actl) injection
Remelimumab-actl injection is used in combination with durvalumab to treat liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).
IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma. Active ingredient: tremelimumab-actl Inactive ingredients: edetate disodium, histidine, L-histidine hydrochloride monohydrate, polysorbate 80,
trehalose, and Water for Injection, USP.
Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase positive mutations.
Drug (Brand / Generic): IMJUDO / tremelimumab-act
Current Indication: treat liver cancer
Approval Date: Aug 1, 2022
AstraZeneca
IMJUDO (tremelimumab-actl) injection is a clear to slightly opalescent, colorless to slightly yellow solution supplied in a carton containing one single-dose vial in the following concentrations:
• 25 mg/1.25 mL (20 mg/mL) (NDC 0310-4505-25)
• 00 mg/15 mL (20 mg/mL) (NDC 0310-4535-30)
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ IMJUDO (tremelimumab-actl) injection ”. Confirmation of the order for IMJUDO (tremelimumab-actl) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – IMJUDO
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.
IMJUDO Sourcing & Delivery
Alleviare India specializes in sourcing and supplying IMJUDO, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of IMJUDO in India.
How much does IMJUDO cost in the India?
Kindly reach out to us for IMJUDO (tremelimumab-actl) injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import IMJUDO to India?
To import tremelimumab IMJUDO, patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
Valid prescription from a qualified doctor.
Patients’ diagnostic reports.
Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
Valid prescription from the doctor.
Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is IMJUDO available in India?
IMJUDO tremelimumab is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of IMJUDO (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for IMJUDO availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is tremelimumab available in India?
On October 21, 2022, the FDA approved tremelimumab (Imjudo) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHC).
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand IMJUDO (tremelimumab-actl) injection . The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to IMJUDO (tremelimumab-actl) injection , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
